*Starting Soon* – Examines the effects of retatrutide weekly injection on cardiovascular outcomes in obese (>35 BMI) patients who have cardiovascular disease.

*Starting Soon* – Examines the effects of small interfering RNA molecule that reduces LPa on Cardiovascular outcomes in patients with raised Lpa and cardiovascular disease.

Examines the effects of ziltivikimab monthly injection on microvascular inflammation and outcomes in Heart failure in heart failure patients with active inflammation.

Examines the effects of retatrutide weekly injections on knee osteoarthritis in obese (>35 BMI) patients who have painful and stiff osteoarthritis of the knees.

Examines the effects of retatrutide weekly injections on cardiovascular outcomes in obese (>35 BMI) patients who have had a heart attack, stroke or have symptomatic peripheral arterial disease.

Examines the effects of ziltivikimab monthly injection on microvascular inflammation and cardiovascular outcomes in patients with atherosclerosis and renal impairment.

Cardiovascular outcome study comparing the cagrilintide combination with Semaglutide (Ozempic) versus placebo in patients with obesity and established cardiovascular disease.

Examines the effects of cagrisema weekly injections on cardiovascular outcomes in obese (>27 BMI) patients who have had cardiovascular disease.

Examines the effects of retatrutide weekly injections on sleep apnea in obese (>27 BMI) patients with diabetes who have sleep apnea.

Examines the effects of inclisarin 6 monthly injections on cardiovascular outcomes in patients with cardiovascular disease and elevated cholesterol despite maximum therapy.